



Current Insights and Future Perspectives into Mechanisms of Drug Resistance in Gastrointestinal Cancers

Guest Editor:

Dr. Mohammed Sikander

Department of Immunology and
Microbiology, Biomedical
Research, The University of Texas
Rio Grande Valley, 5300 North L
Street, McAllen, TX 78504, USA

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editor

This Special Issue will delve into various aspects of drug resistance mechanisms in GI cancers, such as genetic alterations, epigenetic modifications, tumor microenvironment factors, and host immunity. The contributors will present cutting-edge research findings, including novel molecular pathways and signaling networks that drive drug resistance in GI cancers. They will also explore the role of tumor heterogeneity, cancer stem cells, and the interplay between cancer cells and stromal components in promoting resistance.

Moreover, this Special Issue will discuss the clinical implications of drug resistance and its impact on treatment response and patient outcomes. The contributors will critically evaluate the existing therapeutic approaches, including the development of combination therapies, personalized medicine strategies, and the repurposing of drugs to overcome resistance.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)